CAS: 45127-11-5; 2,2'-Disulfanediyldiethanesulfonic Acid

该化合物是甲型生物起源的关键同源物,是甲状腺生成甲烷最后一步的甲基载体,其独特的结构,以硫醇和磺酸盐为特色,能够有效地进行甲基组转移和再氧化反应.Coenzyme M对于研究厌氧微生物新陈代谢和沼气生产过程至关重要.它的高度纯度和稳定性使它对生物化学研究,特别是酶学和环境微生物学的研究具有价值.该化合物在甲烷循环途径中的作用也凸显了其在理解温室气体排放和微生物生态方面的重要性.

结构式图片

上下游产品

CAS号19767-45-4 美司那 | CAS号4263-52-9 2-溴乙基磺酸钠 | CAS号3375-50-6 2-巯基乙磺酸

合成工艺路线路线简述

    📜3,4-Dithia-1,6-Hexan-Disulfonyl-Chlorid置于水体系中,用 乙腈 作为反应溶剂,化学反应 120.0H,以96%的收率获得产物辅酶 M
    参考文献:Medicinal Disulfide Salts
    标题:Medicinal Disulfide Salts
    摘要:这项发明涉及新型药用二硫化物盐.这些化合物包括一个末端磺酸盐或膦酸盐基团,并具有许多用途,例如在与许多抗肿瘤药物一起使用时作为毒性减少剂.

    专利信息


    专利号:EP-1499587-A4
    优先权日:2002-04-30
    标 题:PROCESS FOR SYNTHESIS OF PHARMACEUTICALLY ACTIVE DISULFIDE SALTS

    专利号:US-2009232906-A1
    优先权日:2008-03-14
    标 题 :Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
    发明人:HAUSHEER FREDERICK H
    权利人:BIONUMERIK PHARMACEUTICALS INC
    摘要:The present invention discloses and claims: (i) compositions, methods, and kits which lead to an increase in patient survival time in cancer patients receiving chemotherapy; (ii) compositions and methods which cause cytotoxic or apoptotic potentiation of the anti-cancer activity of chemotherapeutic agents; (iii) compositions and methods for maintaining or stimulating hematological function in patients in need thereof, including those patients suffering from cancer; (iv) compositions and methods for maintaining or stimulating erythropoietin function or synthesis in patients in need thereof, including those patients suffering from cancer; (v) compositions and methods for mitigating or preventing anemia in patients in need thereof, including those patients suffering from cancer; (vi) compositions and methods for maintaining or stimulating pluripotent, multipotent, and unipotent normal stem cell function or synthesis in patients in need thereof, including those patients suffering from cancer; (vii) compositions and methods which promote the arrest or retardation of tumor progression in those cancer patients receiving chemotherapy; (viii) compositions and methods for increasing patient survival and/or delaying tumor progression while maintaining or improving the quality of life in a cancer patient receiving chemotherapy; (ix) novel methods of the administration of taxane and/or platinum medicaments and a Formula (I) compound of the present invention to a cancer patient; and (x) kits to achieve one or more of the aforementioned physiological effects in a patient in need thereof, including those patients suffering from cancer.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Reddy V, Winston NR. Mesna. 2023 Jun 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. 47(3):511-23. doi: 10.1007/s00726-014-1882-0. Epub 2014 Dec 10. 58(19):4358-62. 37(7):618-24. doi: 10.1002/j.1552-4604.1997.tb04344.x. 52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.

    合成参考文献


    参考文献:10.1016/s0959-8049(02)00036-9
    摘要:Boven E, Verschraagen M, Hulscher TM, Erkelens CAM, Hausheer FH, Pinedo HM, van der Vijgh WJF. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. European Journal of Cancer. 2002 May;38(8):1148–56. doi: 10.1016/s0959-8049(02)00036-9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知